PRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, today announced that it has purchased the MEDIHONEY® brand ...

PRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced a $7.0 million strategic investment in ...

Wound-care products maker Derma Sciences Inc. said today it has raised $6.1 million in gross proceeds under agreements to sell the company’s stocks and warrants to new and existing ...

PRINCETON, N.J.--(BUSINESS WIRE)-- Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced that it has been awarded a research ...

Derma Science Inc., a Princeton-based tissue regeneration company, announced Monday that its board of directors has appointed Stephen T. Wills to serve as interim executive chairman and principal ...

Derma Sciences Inc (NASDAQ:DSCI) has experienced an increase in hedge fund interest of late. At the moment, there are a multitude of indicators investors can use to watch their holdings. Some of the ...

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today reported financial and operating results for the three and six months ended June ...

Since 1996, Ed Quilty has been at the helm of Derma Sciences (DSCI), maker of the popular MEDIHONEY wound care products. Now, the company is in the final stages of a new wound-healing product.

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced positive results from its Phase 2 clinical trial with DSC127 in ...

Barry Wolfenson, 609-514-4744Executive Vice President of Marketing and Business DevelopmentorKim Sutton Golodetz, 212-838-3777orBruce Voss, 310-691-7100@LHA_IR_PRorMackenzie Mills, 212-838-3777orJ.

Derma Sciences (NASDAQ: DSCI) filed its 10-K on March 28. Here are the numbers you need to know. The 10-second takeaway For the quarter ended Dec. 31 (Q4), Derma Sciences met expectations on revenues ...